Literature DB >> 1693335

Oral immunotherapy with grass pollen in enterosoluble capsules. A prospective study of the clinical and immunological response.

R Urbanek1, K H Bürgelin, S Kahle, W Kuhn, U Wahn.   

Abstract

In a prospective study spanning 2 years, 60 patients with grass pollen allergy were treated with either a low dose oral, a high dose oral or a subcutaneous hyposensitization regime. No significant improvement was seen in the orally treated patients whereas those on the subcutaneous hyposensitization regime demonstrated a decreased specific cutaneous reactivity, a rise in specific IgG antibodies and a reduction in symptoms. This study suggests that oral hyposensitization, even with enterosoluble grass pollen capsules, is ineffective.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693335     DOI: 10.1007/bf01957689

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  20 in total

1.  A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies.

Authors:  L M Lichtenstein; P S Norman; W L Winkenwerder
Journal:  Ann Intern Med       Date:  1971-11       Impact factor: 25.391

2.  Leukocyte histamine release and humoral changes during oral and subcutaneous hyposensitization of grass pollen allergic children.

Authors:  U Wahn; H J Maasch; W Geissler
Journal:  Helv Paediatr Acta       Date:  1984-05

3.  Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever.

Authors:  P S Norman; L M Lichtenstein; A Kagey-Sobotka; D G Marsh
Journal:  J Allergy Clin Immunol       Date:  1982-10       Impact factor: 10.793

4.  A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy.

Authors:  L C Grammer; M A Shaughnessy; I M Suszko; J J Shaughnessy; R Patterson
Journal:  J Allergy Clin Immunol       Date:  1983-11       Impact factor: 10.793

5.  Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study.

Authors:  C Möller; S Dreborg; A Lanner; B Björkstén
Journal:  Allergy       Date:  1986-05       Impact factor: 13.146

6.  Correlation of IgG and IgE antibody levels to honey bee venom allergens with protection to sting challenge.

Authors:  D R Hoffman; S A Gillman; L H Cummins; P P Kozak; A Oswald
Journal:  Ann Allergy       Date:  1981-01

7.  Oral immunotherapy in birch pollen hay fever.

Authors:  E Taudorf; L C Laursen; A Lanner; B Björksten; S Dreborg; M Søborg; B Weeke
Journal:  J Allergy Clin Immunol       Date:  1987-08       Impact factor: 10.793

8.  Dose response of IgE and IgG antibodies during ragweed immunotherapy.

Authors:  P S Creticos; T E Van Metre; M R Mardiney; G L Rosenberg; P S Norman; N F Adkinson
Journal:  J Allergy Clin Immunol       Date:  1984-01       Impact factor: 10.793

9.  Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospective study.

Authors:  W Rebien; E Puttonen; H J Maasch; E Stix; U Wahn
Journal:  Eur J Pediatr       Date:  1982-07       Impact factor: 3.183

10.  Systemic tolerance and secretory immunity after oral immunization.

Authors:  S J Challacombe; T B Tomasi
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

View more
  4 in total

1.  Pollen grains for oral vaccination.

Authors:  Shashwati U Atwe; Yunzhe Ma; Harvinder Singh Gill
Journal:  J Control Release       Date:  2014-08-23       Impact factor: 9.776

Review 2.  Induction of tolerance via the sublingual route: mechanisms and applications.

Authors:  Philippe Moingeon; Laurent Mascarell
Journal:  Clin Dev Immunol       Date:  2011-11-10

Review 3.  Allergen immunotherapy: routes, safety, efficacy, and mode of action.

Authors:  Jillian Leigh Hochfelder; Punita Ponda
Journal:  Immunotargets Ther       Date:  2013-07-22

4.  Effectiveness and safety of oral lactococci-based vaccine encoding triple common allergens to prevent airway allergy in mice.

Authors:  Mey-Fann Lee; Chu-Hui Chiang; Shyh-Jye Lin; Chi-Sheng Wu; Yi-Hsing Chen
Journal:  PLoS One       Date:  2021-12-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.